Welcome: Guest | Site Use Options | Register | Login |

La Jolla Pharmaceutical Company

4365 Executive Drive Suite 1070
San Diego, CA 92122
www.ljpc.com
Public
OTC:LJPC
 Synopsis: Business Condition
Year Founded 1989
Employment 4
Sector Healthcare
Industry Biotechnology
La Jolla Pharmaceutical Company
     Last modified on: 7/2/2013

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company’s products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

  

SBIR firms in the news



Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com